LianBio Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
LianBio (LIANY) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $1.11 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-28.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2023-03-28
- LianBio right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-12-31 was -$123.00K, a 102.50% decline year-over-year.
- LianBio right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- LianBio right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $4.91M, a 11065.91% increase year-over-year.
- LianBio right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $247.00K.
- LianBio right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $1.11M, a 78.49% decline from fiscal 2021.
- LianBio right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $5.16M, a 275.27% increase from fiscal 2020.
- LianBio right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $1.38M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$123.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$123.00K derived: sum of 2 quarters · filed 2023-03-28 | $1.11M 10-K · filed 2023-03-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.23M 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $1.23M 10-Q · filed 2022-08-11 | |||
| 2021-12-31 | $4.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $5.16M derived: sum of 2 quarters · filed 2023-03-28 | $5.16M 10-K · filed 2023-03-28 | |
| 2021-09-30 | $247.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $247.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-11 | |||
| 2020-12-31 | $44.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2022-03-31 | $1.38M 10-K · filed 2022-03-31 | ||
| 2020-09-30 | $1.33M 10-Q/A · filed 2022-01-10 |